
Loading, please wait...

Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
— Hippocrates

Semaglutide in India is becoming significantly more affordable as domestic pharmaceutical companies enter the market with cheaper alternatives. Consequently, experts believe this shift will fundamentally change how clinicians treat obesity and type 2 diabetes across the country. However, medical professionals warn that this medication is not a "magic fix" for weight loss. Therefore, patients must use it under strict medical supervision to avoid complications.
The entry of multiple Indian pharmaceutical companies has triggered a massive price reduction. Estimates suggest that prices for semaglutide shots will drop by 60 to 80 percent soon. Moreover, this increased affordability allows a broader demographic to access advanced GLP-1 receptor agonist therapy. Dr. V. Mohan notes that earlier versions were already cheaper in India than in the US. However, current competition will make these life-altering drugs even more accessible to the general population. Besides affordability, clinicians observe that patients are now more aware of these therapies. Furthermore, some centers report successful reversals of diabetes in obese patients using these medications.
Despite the benefits, doctors express significant concerns regarding cosmetic misuse. Specifically, many individuals view the drug as a slimming agent rather than a chronic disease medication. This trend is often fueled by celebrity transformations seen on social media platforms. Additionally, the risk of over-medicalization remains a serious threat to public health. Dr. Satish Koul highlights that off-label use was already prevalent even before patents expired. Consequently, the CDSCO emphasizes that only qualified doctors should prescribe these drugs. Furthermore, unauthorized access through gyms or online platforms constitutes dangerous misuse. Therefore, tighter regulations are necessary to ensure patient safety and drug efficacy.
Common side effects of semaglutide include gastrointestinal issues like nausea, vomiting, and diarrhea. Moreover, rare but serious risks include pancreatitis and stomach paralysis. Patients must also understand that weight regain is almost certain if they discontinue the medication abruptly. Therefore, long-term adherence is essential for maintaining therapeutic results. Additionally, reliance on medication alone is insufficient for managing chronic obesity. Clinicians stress that diet and exercise remain the cornerstones of effective treatment. Finally, healthcare providers must monitor patients closely to adjust dosages and manage adverse events.
Q1: Is semaglutide a permanent solution for weight loss?
No, experts warn that weight regain is almost 100% if the drug is stopped. It should be treated as a long-term therapy for chronic disease management rather than a temporary fix.
Q2: What are the primary side effects of semaglutide?
The most common side effects are gastrointestinal, including nausea, vomiting, and diarrhea. Nausea alone can affect up to 50% of patients during the initial stages of treatment.
Q3: Can I buy semaglutide without a prescription in India?
No, the CDSCO and DCGI mandate that only qualified doctors should prescribe this medication. Using it without professional supervision is considered misuse and can lead to serious health risks.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Indian pharma price drops for semaglutide make obesity and diabetes care more accessible, but doctors warn against cosmetic misuse and rebound weight gain....
2 months ago

A recent study shows that seasonal vaccines boost antibody titres against H3N2 subclade K variants in adults. This research highlights why human serologic data is essential for accurate vaccine strain selection compared to ferret models.
Today

A nationwide Belgian study reveals that while invasive lobular carcinoma (ILC) has comparable 5-year survival to other breast cancers, its 10-year prognosis is significantly worse, particularly due to late recurrences in Luminal subtypes.
Today

Evidence suggests SGLT2 inhibitors may offer a disease-modifying strategy for aortic stenosis. By targeting valve calcification and myocardial remodeling, these drugs could slow disease progression and improve outcomes in patients with chronic pressure overload.
Today

A systematic review highlights the prevalence of work-related musculoskeletal disorders (WMSDs) in airport staff, particularly baggage handlers. The study emphasizes the need for better ergonomic interventions and regulatory frameworks to protect workers from lower back, neck, and shoulder injuries.
Today

Pneumothorax after thyroid or parathyroid surgery is rare (0.10%) but carries severe clinical risks. This study shows it is linked to a 16-fold increase in 1-year mortality and higher rates of pneumonia, dysphagia, and hospital readmissions, necessitating vigilant postoperative monitoring.
Today